Michael W. Koempel
Thank you, Michael, and thank you, everyone, for joining us today. On a consolidated basis, we grew top line revenues 9% in the second quarter, our strongest year-over-year growth since the third quarter of last year. Our largest business, Branded Products, grew revenues by 14%, driven by the timing of orders delivered, organic expansion with existing large enterprise accounts, including higher tariffs and revenues generated by 3 Point following its acquisition in December 2024. For Healthcare Apparel, we grew revenues by 6% over the second quarter of last year from volume increases in Wink and Carhartt products. Our contact center business saw a 3% decline in revenues versus the year ago quarter as continued macroeconomic headwinds resulted in customer downsizing and attrition outpacing new customer acquisition. While our sales activity has picked up and our sales force drove the pipeline to a record high, we are experiencing a slower pace of new customer acquisition due to the delay in decision- making from prospective customers that Michael previously mentioned. Our consolidated gross margin was about flat versus last year's second quarter at 38.4%, but up 160 basis points sequentially. SG&A at 36.3% of sales improved from 36.9% in the year ago quarter despite recognizing $1.8 million in credit loss reserves across the Branded Products and Contact Center segment during the second quarter due to customer bankruptcies. The SG&A rate improvement was driven by leverage on the 9% sales increase as well as the benefit from cost reduction actions that we disclosed in the prior quarter. Putting together our stronger revenue with steady gross margin and improved SG&A performance, we generated EBITDA of $6.1 million, up from $5.6 million in the year earlier period. Turning to performance by segment. For Branded Products, we saw a 100 basis point improvement in gross margin to 35.6%, driven by favorable customer sales mix. The SG&A rate for Branded products also improved to 27.5% versus 28.3% in the second quarter of last year, benefiting from leverage on the significant sales increase for the quarter. As a result, Branded products drove strong improvement in quarterly EBITDA to $9 million, up from $6.7 million a year earlier. As for Healthcare Apparel, our gross margin of 35.5% decreased from 38.4% a year earlier due to higher cost of goods, including the recently enacted higher tariff costs in advance of price increases to our customers. Conversely, we are able to hold the line on controllable expenses and SG&A came in at 35.7% of sales, which was 150 basis points better than the second quarter of 2024, driven by higher sales during the quarter. Overall, our healthcare apparel EBITDA of $800,000 was down modestly from $1.3 million the prior year. Moving on to contact centers. We drove a slightly higher gross margin of 52.6%, up 40 basis points year-over-year. However, the SG&A as a percentage of revenues increased to 48.4% as compared to 42.4% in the year ago quarter, primarily due to a $1.1 million credit loss reserve resulting from the solar customer bankruptcy during the quarter. Therefore, contact center EBITDA of $1.6 million was down from $3.2 million a year earlier. Turning to net interest expense. The second quarter was $1.3 million, which compares favorably to $1.5 million in the second quarter a year ago, benefiting from a lower weighted average interest rate. Putting it all together, we returned to profitability this quarter with net income of $1.6 million, up from the prior year second quarter's net income of $600,000. On a per share basis, we produced earnings per diluted share of $0.10, up from $0.04 compared to the year ago quarter. Moving on to the balance sheet. At the end of June, we had $21 million in cash and cash equivalents, up from $19 million at the beginning of the year. We continue to actively buy back our own common shares during the quarter as an attractive use of capital, repurchasing about 390,000 shares for approximately $4 million, resulting in an average purchase price of $10.26 per share. We ended the quarter with $12.3 million remaining under our current buyback authorization of $17.5 million. Taking into account our operating cash flow, share repurchases and consistent dividend, our net leverage ratio at the end of June was 2.2x trailing 12-month covenant EBITDA, consistent with the first quarter and up from 1.7x at the start of the year. We have significant liquidity to execute on our growth plans while continuing to return capital when possible to shareholders, and we remain well within our covenant requirements. I'll wrap up with our full year outlook, which is unchanged from last quarter as we still expect revenues to be in the range of $550 million to $575 million, suggesting year-over-year growth at the high end of about 2%. While our clients across all 3 business lines continue to face uncertainty regarding inflation, interest rates, tariff duties and other macro factors, we're well positioned to support their needs regardless of the economic environment, given our strong liquidity and the costs we've already removed from the business while continuing to invest in our own favorable growth prospects. And now operator, if you could please open the line, Michael, Jake and I would be happy to take questions.